Transatlantic lipid guideline divergence: same data but different interpretations
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Despite consensus that excessive circulating concentrations of apoB-lipoproteins is a key driver for the atherosclerotic process and that treatments that low-density lipoprotein cholesterol lowering by up-regulation of low-density lipoprotein cholesterol receptor expression reduces that risk, divergent viewpoints on interpretation of study data have resulted in substantial differences in European and American lipid guideline recommendations. This article explores those differences and highlights the importance of understanding guideline-based lipid management to improve patient care and reduce the risk of clinical atherosclerotic cardiovascular disease.
Date Issued
2020-11-03
Date Acceptance
2020-08-26
Citation
Journal of the American Heart Association, 2020, 9 (21), pp.e018189-e018189
ISSN
2047-9980
Publisher
Wiley
Start Page
e018189
End Page
e018189
Journal / Book Title
Journal of the American Heart Association
Volume
9
Issue
21
Copyright Statement
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/33092440
Subjects
guideline
risk assessment
therapy
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2020-10-23